Bokf Na Invests $936,000 in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

BOKF NA bought a new stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 10,772 shares of the company's stock, valued at approximately $936,000.

Other hedge funds also recently bought and sold shares of the company. Raleigh Capital Management Inc. purchased a new position in PROCEPT BioRobotics during the fourth quarter worth about $32,000. Thematics Asset Management acquired a new stake in PROCEPT BioRobotics during the 4th quarter worth $46,000. Signaturefd LLC boosted its holdings in shares of PROCEPT BioRobotics by 26.7% in the fourth quarter. Signaturefd LLC now owns 689 shares of the company's stock valued at $55,000 after acquiring an additional 145 shares during the period. IFP Advisors Inc purchased a new stake in shares of PROCEPT BioRobotics during the fourth quarter worth approximately $58,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of PROCEPT BioRobotics in the 3rd quarter worth $64,000. Hedge funds and other institutional investors own 89.46% of the company's stock.

PROCEPT BioRobotics Stock Performance

NASDAQ PRCT traded up $1.36 during trading on Wednesday, hitting $54.40. The company's stock had a trading volume of 550,685 shares, compared to its average volume of 807,611. The firm has a market cap of $3.01 billion, a P/E ratio of -27.90 and a beta of 1.10. PROCEPT BioRobotics Co. has a 52 week low of $47.04 and a 52 week high of $103.81. The firm has a 50 day moving average price of $55.33 and a 200 day moving average price of $72.66. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.04. The firm had revenue of $69.16 million for the quarter, compared to analysts' expectations of $65.39 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The business's revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.51) earnings per share. Equities research analysts forecast that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Reza Zadno sold 5,475 shares of the business's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the sale, the chief executive officer now directly owns 173,070 shares in the company, valued at approximately $9,875,374.20. The trade was a 3.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Kevin Waters sold 733 shares of PROCEPT BioRobotics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the transaction, the chief financial officer now directly owns 107,991 shares of the company's stock, valued at $6,161,966.46. The trade was a 0.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,455 shares of company stock worth $368,322 in the last 90 days. Company insiders own 6.60% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on PRCT. Bank of America decreased their price objective on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a research report on Friday, April 25th. Truist Financial lowered their price target on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, April 11th. Finally, Morgan Stanley cut their price objective on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, PROCEPT BioRobotics has a consensus rating of "Moderate Buy" and an average price target of $90.00.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).